Jubbonti
Jubbonti
Jubbonti® (denosumab-bbdz) is an FDA-approved medicine (subcutaneous injection) that is used to treat osteoporosis. It is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures.
Jubbonti helps to strengthen bones and reduce the risk of fractures (broken bones). Jubbonti is a biosimilar to Prolia®, which means it can be used in place of Prolia.
Administration Information
The recommended dose of Jubbonti is 60 mg administered as a single subcutaneous injection once every 6 months.
Potential Side Effects
The most common side effects of Jubbonti in women who are being treated for osteoporosis after menopause are back pain, pain in your arms and legs, high cholesterol, muscle pain, and bladder infection. The most common adverse reactions leading to discontinuation in patients with postmenopausal osteoporosis are back pain and constipation.
The most common side effects of Jubbonti in men with osteoporosis are back pain, joint pain, and common cold (runny nose or sore throat).
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Jubbonti. Call your doctor for medical advice about side effects.Please see full Prescribing Information for Jubbonti, including Boxed Warning and Medication Guide.
Helpful Resources
Jubbonti stops some of the cells that remove bone from working. This helps create balance between the cells that are removing bone and the cells that are replacing it. When this happens, bones become stronger and the risk of breaking a bone is lower.
Jubbonti is a biosimilar to Prolia® (denosumab) and can be used in its place. This means that there are no differences between the 2 medicines when it comes to safety and effectiveness
There are no differences between a biosimilar and a name-brand medicine when it comes to safety and effectiveness. You can expect the same results with a biosimilar as you have had with a name-brand medicine.
About Jubbonti:
Patient Support Program:
Sage Infusion Tips for Osteoporosis
Before you attend your first appointment at Sage Infusion, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices, Patient Rights and Responsibilities, and Appointment Lateness and Cancelation are for reference only. Please contact us if you have any questions!
Patient Consent Form
HIPAA Privacy Authorization Form
Notice of Privacy Practices
Patient Rights and Responsibilities
Appointment Lateness and Cancelation
Find a Sage Infusion Location Near You
We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.
SEARCH BY ZIP
Southwest Florida
Tampa Bay